Matches in Wikidata for { <http://www.wikidata.org/entity/Q64150429> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q64150429 description "clinical trial" @default.
- Q64150429 description "ensayu clínicu" @default.
- Q64150429 description "klinisch onderzoek" @default.
- Q64150429 description "клінічне випробування" @default.
- Q64150429 name "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)." @default.
- Q64150429 type Item @default.
- Q64150429 label "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)." @default.
- Q64150429 prefLabel "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)." @default.
- Q64150429 P1132 Q64150429-8D2E2E2B-BB40-4A15-93B7-08A1E5CFC57A @default.
- Q64150429 P1476 Q64150429-34668E7A-BA3D-4B38-95D8-DCBCEBC266C7 @default.
- Q64150429 P17 Q64150429-11D40AB4-0026-4111-B164-D297BC70C435 @default.
- Q64150429 P17 Q64150429-31B4EAE1-6193-47AE-AEB2-8DAA55608553 @default.
- Q64150429 P17 Q64150429-439345D6-7F58-4B67-A155-E79A301A7C51 @default.
- Q64150429 P17 Q64150429-59474D17-F728-4AA1-BF32-25268A56ECA6 @default.
- Q64150429 P17 Q64150429-7A1EACBE-11F7-4173-B652-0E676EBF07DD @default.
- Q64150429 P17 Q64150429-833886BD-4C3F-41B7-A1E0-44A9ECF8ED4F @default.
- Q64150429 P17 Q64150429-A8C7A7BF-08FD-4952-92C5-C24D75817522 @default.
- Q64150429 P17 Q64150429-C1A20841-15D8-4FD6-BC55-EB8610C0F2F6 @default.
- Q64150429 P1813 Q64150429-A4F24790-574F-462D-B387-F3A3C6D88622 @default.
- Q64150429 P2899 Q64150429-FC682039-8A62-4D1F-A512-950C37478B08 @default.
- Q64150429 P3098 Q64150429-EC7908FC-E7C9-474B-AFC7-3691FD46059F @default.
- Q64150429 P31 Q64150429-D679BECB-6FFF-4840-82AD-200EA299E5AE @default.
- Q64150429 P4844 Q64150429-3481829D-19D1-458F-AD38-AEC08C078E40 @default.
- Q64150429 P4844 Q64150429-407042DA-2C94-419C-BF82-BB61A48C9CA0 @default.
- Q64150429 P4844 Q64150429-4CBD2275-9E54-488A-8113-7FEB70763601 @default.
- Q64150429 P4844 Q64150429-C29510F5-C83A-4CC2-9606-3FC847FA8F72 @default.
- Q64150429 P4844 Q64150429-CE12C95E-A137-407C-8E93-F1F912ED4AC5 @default.
- Q64150429 P580 Q64150429-781BE84A-E9F5-4CD2-9039-BCACDF335E34 @default.
- Q64150429 P582 Q64150429-B8390C59-943A-4A9F-A6A3-264B0B717B48 @default.
- Q64150429 P6099 Q64150429-CAF0EB0A-BB46-4629-865E-3B0BBB04FE8B @default.
- Q64150429 P8363 Q64150429-F99C3B70-B1B6-4F4C-AAFE-BB6820BC94CD @default.
- Q64150429 P1132 "+216" @default.
- Q64150429 P1476 "A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)." @default.
- Q64150429 P17 Q142 @default.
- Q64150429 P17 Q145 @default.
- Q64150429 P17 Q183 @default.
- Q64150429 P17 Q29 @default.
- Q64150429 P17 Q30 @default.
- Q64150429 P17 Q36 @default.
- Q64150429 P17 Q408 @default.
- Q64150429 P17 Q664 @default.
- Q64150429 P1813 "KEYNOTE-799" @default.
- Q64150429 P2899 "+18" @default.
- Q64150429 P3098 "NCT03631784" @default.
- Q64150429 P31 Q30612 @default.
- Q64150429 P4844 Q13896859 @default.
- Q64150429 P4844 Q412415 @default.
- Q64150429 P4844 Q415220 @default.
- Q64150429 P4844 Q415588 @default.
- Q64150429 P4844 Q423762 @default.
- Q64150429 P580 "2018-10-19T00:00:00Z" @default.
- Q64150429 P582 "2020-12-15T00:00:00Z" @default.
- Q64150429 P6099 Q42824440 @default.
- Q64150429 P8363 Q78089383 @default.